Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
BermudaIPO:
06 August 2014Website:
http://altamiratherapeutics.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:45:15 GMTDividend
Analysts recommendations
Institutional Ownership
CYTO Latest News
Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today highlighted the publication of an article describing the rationale for and use of betahistine in the treatment of residual dizziness following standard of care physical repositioning procedures for benign paroxysmal positional vertigo (BPPV). The peer reviewed article was published by an international group of medical and scientific experts in vestibular disorders in the journal Frontiers in Neurology1 and reviews the potential causes of residual dizziness, which has been reported to occur in 31-61% of patients, and available treatment options.
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update related to its RNA delivery platform, partnering of its legacy assets, corporate structuring and financial reporting.
HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Special Call December 11, 2023 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman and CEO Conference Call Participants Operator Good morning, and welcome to Altamira Therapeutics December 23, 2023 Investor Business Update Conference Call.
Altamira Therapeutics (NASDAQ: CYTO ) stock isn't doing so hot on Monday after the company was given a delisting notice last week. That delisting notice comes from the Listing Qualifications Department of the Nasdaq Exchange.
Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday's Thanksgiving Holiday and one of the “Magnificent Seven” could become a major catalyst.
Among the leading gainers in the market today, Altamira Therapeutics (NASDAQ: CYTO ) is certainly raising eyebrows. In earlier trading, shares of the biotech company focused on RNA-based therapeutics more than tripled.
Altamira Therapeutics (NASDAQ: CYTO ) stock is rising higher on Friday despite a lack of news from the biopharmaceutical company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2023 Earnings Conference Call September 12, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman & CEO Covadonga Paneda - Chief Operating Officer Conference Call Participants Operator Good morning, and welcome to the Altamira Therapeutics First Half 2023 Financial Results and Business Update Conference Call.
If you're looking for the best penny stocks to buy today, you should be well-prepared to deal with high volatility. Whether it's the latest debt ceiling crisis, pandemic fear reemerging, today's Fed meeting minutes from May, or speeches by Janet Yellen and Federal Reserve members, there are plenty of headlines to contend with.
What type of business is Altamira Therapeutics?
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
What sector is Altamira Therapeutics in?
Altamira Therapeutics is in the Healthcare sector
What industry is Altamira Therapeutics in?
Altamira Therapeutics is in the Biotechnology industry
What country is Altamira Therapeutics from?
Altamira Therapeutics is headquartered in Bermuda
When did Altamira Therapeutics go public?
Altamira Therapeutics initial public offering (IPO) was on 06 August 2014
What is Altamira Therapeutics website?
https://altamiratherapeutics.com
Is Altamira Therapeutics in the S&P 500?
No, Altamira Therapeutics is not included in the S&P 500 index
Is Altamira Therapeutics in the NASDAQ 100?
No, Altamira Therapeutics is not included in the NASDAQ 100 index
Is Altamira Therapeutics in the Dow Jones?
No, Altamira Therapeutics is not included in the Dow Jones index
When does Altamira Therapeutics report earnings?
Next earnings report date is not announced yet